Paris, November 4, 2009 - Cellectis bioresearch, a specialist in genome customization and a subsidiary of Cellectis S.A. (Alternext: ALCLS), today launched cGPS^® CHO-S CEMAX^®, a kit which enables targeted integration into suspension cell cultures. By reducing the amount of time required to obtain clones and by improving production stability, this kit represents an advancement in the production of recombinant proteins and monoclonal antibodies. It will make producing antibodies for research and diagnostic easier.